
Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Cystatin E/M stops inflammation that cervical cancer cells need to grow.

Breast cancer cells found to hide in bone marrow before resurging.

Pancreatic cancer patients whose tumors surround critical blood vessels may have new treatment options.

Immunotherapy for lung cancer patients may cause other conditions to become worse.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

Vitamin A combined with Gemzar found to reduce proliferation of cancer cells.

Researchers still urge physicians to use caution utilizing light phototherapy for jaundice infants.

Xilonix is the first monoclonal antibody immunotherapy that targets and neutralizes interleukin-1 alpha.

Malignant brain tumor cells found to rely on fats for energy and growth.

Radiation therapy with checkpoint inhibitors offers promise for skin cancer therapy.

Top news of the day from across the health care landscape.

Researchers were able to better predict the risk of developing breast cancer.

System provides images deep within tumor tissue.

On February 17, 2017, a pharmacist will be climbing Mount Kilimanjaro to support the Multiple Myeloma Research Foundation.

Concern persists among physicians who treat HIV-associated lymphoma with stem cell transplants due to the risk of harming the immune system.

Mice without the LRH-1 protein develop less liver cancers than mice who had the protein.

Olive oil-based emulsion may help boost efficacy of bladder cancer therapy.

Approximately 58% of patients with nonalcoholic steatohepatitis treated with pioglitazone showed reduced disease activity.

Photodynamic therapy for skin cancer can cause immense burning pain to patients.

The protein GlyRS helps modify proteins that cause cancer growth.

Research may lead to new treatments for ovarian cancer.

Doxorubicin, all-trans retinoic acid, and entinostat significantly reduced triple-negative breast cancer tumors in mice.

Driver mutations in lung adenocarcinoma and lung squamous cell carcinoma differ from one another, contradictory to previous theories.

Findings improve the ability of providers to monitor the development of melanoma.

Anthrax toxin proteins are able to control tumor growth.

If cancerous tumors have an addiction to a gene, an inhibitor can be administered that can stop cell growth.

Postmenopausal patients with invasive ductal carcinomas had high levels of saturated fats.